APA (7th ed.) Citation

JS, B., ME, M., M, S., P, C., MD, F., & RE, M. (2022). Envisioning the development of a CRISPR-Cas mediated base editing strategy for a patient with a novel pathogenic CRB1 single nucleotide variant. Ophthalmic genetics, 43(5), 661. https://doi.org/10.1080/13816810.2022.2073599

Chicago Style (17th ed.) Citation

JS, Bellingrath, McClements ME, Shanks M, Clouston P, Fischer MD, and MacLaren RE. "Envisioning the Development of a CRISPR-Cas Mediated Base Editing Strategy for a Patient with a Novel Pathogenic CRB1 Single Nucleotide Variant." Ophthalmic Genetics 43, no. 5 (2022): 661. https://doi.org/10.1080/13816810.2022.2073599.

MLA (9th ed.) Citation

JS, Bellingrath, et al. "Envisioning the Development of a CRISPR-Cas Mediated Base Editing Strategy for a Patient with a Novel Pathogenic CRB1 Single Nucleotide Variant." Ophthalmic Genetics, vol. 43, no. 5, 2022, p. 661, https://doi.org/10.1080/13816810.2022.2073599.